GSK-690693 is an inhibitor of Akt that displays anticancer chemotherapeutic activity. In lung and colon cancer cells, GSK-690693 inhibits cell growth. In animal models of osteosarcoma, this compound increases survival rates and decreases tumor growth. In other transgenic animal models, GSK-690693 delays lung tumor formation, decreases cell proliferation, and induces apoptosis.
| Cas No. | 937174-76-0 |
|---|---|
| Purity | ≥99% |
| Formula | C21H27N7O3 |
| Formula Wt. | 425.48 |
| IUPAC Name | 4-{2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-[(3S)-3-piperidinylmethoxy]-1H-imidazo[4,5-c]pyridin-4-yl}-2-methyl-3-butyn-2-ol |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | G7242 Info Sheet PDF |
|---|
Nguyen T, Coover RA, Verghese J, et al. Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation. ACS Med Chem Lett. 2014 Mar 7;5(5):462-7. PMID: 24900862.
Carol H, Morton CL, Gorlick R, et al. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Dec 15;55(7):1329-37. PMID: 20740623.
Altomare DA, Zhang L, Deng J, et al. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res. 2010 Jan 15;16(2):486-96. PMID: 20075391.
